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Abstract
Background: Devil Facial Tumour Disease (DFTD) is a unique clonal cancer that threatens the world’s largest carnivorous
marsupial, the Tasmanian devil (Sarcophilus harrisii) with extinction. This transmissible cancer is passed between individual
devils by cell implantation during social interactions. The tumour arose in a Schwann cell of a single devil over 15 years ago
and since then has expanded clonally, without showing signs of replicative senescence; in stark contrast to a somatic cell
that displays a finite capacity for replication, known as the ‘‘Hayflick limit’’.
Methodology/Principal Findings: In the present study we investigate the role of telomere length, measured as Telomere
Copy Number (TCN), and telomerase and shelterin gene expression, as well as telomerase activity in maintaining
hyperproliferation of Devil Facial Tumour (DFT) cells. Our results show that DFT cells have short telomeres. DFTD TCN does
not differ between geographic regions or between strains. However, TCN has increased over time. Unlimited cell
proliferation is likely to have been achieved through the observed up-regulation of the catalytic subunit of telomerase
(TERT) and concomitant activation of telomerase. Up-regulation of the central component of shelterin, the TRF1-intercating
nuclear factor 2 (TINF2) provides DFT a mechanism for telomere length homeostasis. The higher expression of both TERT
and TINF2 may also protect DFT cells from genomic instability and enhance tumour proliferation.
Conclusions/Significance: DFT cells appear to monitor and regulate the length of individual telomeres: i.e. shorter
telomeres are elongated by up-regulation of telomerase-related genes; longer telomeres are protected from further
elongation by members of the shelterin complex, which may explain the lack of spatial and strain variation in DFT telomere
copy number. The observed longitudinal increase in gene expression in DFT tissue samples and telomerase activity in DFT
cell lines might indicate a selection for more stable tumours with higher proliferative potential.
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Introduction
The world’s largest carnivorous marsupial, the Tasmanian devil
(Sarcophilus harrisii) has recently become threatened with extinction
due to a unique transmissible cancer, Devil Facial Tumour Disease
(DFTD) [1,2,3]. Prior to the emergence of the disease, devils were
common throughout Tasmania. However, since the first sighting
of DFTD in 1996, the disease has spread across the island state,
resulting in population declines of up to 90% [3]. The disease now
occurs in over 80% of the devil’s geographic range, and the rapid
population decline has led to the Tasmanian devil being listed as
endangered by international (International Union for Conserva-
tion of Nature [4]) as well as national and state authorities [5].
DFTD is transmitted between individuals by biting during social
interactions [6] and manifests in gross malignant tumours around
the oral cavity, with frequent metastases to other organs [7,8]. Due
to starvation, secondary infections and organ failures, devils
usually succumb to the disease within 6 months of tumour
emergence [1,7]. Cytogenetic analyses have revealed that DFTD
is caused by a rogue clonal cell line [9], that is likely derived from
cells of the neural crest lineage (Schwann cells) [8,10]. Although
DFTD possesses a highly rearranged genome, and is characterised
by tumour specific complex translocations and chromosomal
rearrangements, the cell line is remarkably (chromosomally) stable
[9]. Recently however, four, closely related but karyotypically
distinct DFT strains have been identified, suggesting that the
tumour is evolving [11,12]. Despite the four distinct DFT strains,
genetic studies using microsatellite and immune-gene markers
have demonstrated that Devil Facial Tumour (DFT) cells are
genetically identical [10,13,14,15].
Since their emergence in 1996 [9] DFT cells have undergone
continuous division and propagation in thousands of devils without
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exhausting their capacity for replication and compromising their
genomic stability. In contrast, normal human somatic cells display
a finite capacity for replication, known as the ‘‘Hayflick limit’’[16].
That is, after a given number of divisions, the cells exhaust their
replicative potential due to shortened telomeres and enter a state
known as replicative senescence. In hyperproliferative diseases,
such as tumourigenesis, when telomere attrition reaches a critical
level, cells enter a stage of growth arrest referred to as ‘‘crisis’’
[17,18,19]. By up-regulating or reactivating the telomere terminal
transferase enzyme (telomerase), cancer cells are able to emerge
from the ‘‘crisis’’ state and maintain telomeres that are slightly
longer than those observed during ‘‘crisis’’ [17,20].
Telomeres are ribonucleoprotein complexes at the ends of
eukaryotic chromosomes essential in regulating cell lifespan [18].
Their primary functions are to ensure correct chromosome
segregation during mitosis, and to prevent chromosome fusion
and concomitant cell-cycle arrest, caused by the end of the
chromosomes being treated as DNA double-strand breaks [21]. In
vertebrates, including Tasmanian devils, telomeres consist of
variable numbers of tandem repeats (TTAGGG nucleotides)
bound by a specialised multiprotein complex known as shelterin
[22,23]. Telomere length homeostasis in germ line and tumour
cells is achieved through the negative feedback loop of the
shelterin complex and the telomere terminal transferase enzyme
[24]. Telomerase is activated in pluripotent embryonic, and adult
stem cells, to arrest the progressive telomere attrition through the
addition of TTAGGG repeats to the 39 strand of chromosomes
[24]. Most human tumour cell lines have stable telomere settings,
which are achieved by the negative regulation of the telomerase by
the shelterin complex [25]. The shelterin complex consists of three
shelterin subunits: TRF1, TRF2 and POT1, which are intercon-
nected by three additional proteins TPP1, RAP1 and TINF2.
TINF2 (TRF1-interacting nuclear factor 2, or also called TRF1-
Interacting Nuclear protein 2 (TIN2)) occupies a central position in
the protein complex, by providing a bridge between the
subcomponents of shelterin (for review see [26]). It has been
shown that low expression of TINF2 has a destabilising effect on
shelterin [27,28]. Due to the central and critical role of TINF29
(TIN2) in shelterin stability we chose to measure the expression of
this gene, as a proxy of shelterin activity.
The accumulation of shelterin along the telomeric repeat array
prevents further telomerase induced telomere elongation [23].
Human cancer studies have shown that the joint up-regulation of
telomerase expression and the genes of the shelterin complex may
facilitate in stabilising the cancer cells by preventing the activation
of DNA damage responses, such as apoptosis[27]. In approxi-
mately 85% of human cancers, telomerase activity has been shown
to facilitate malignant transformation by maintaining replicative
potential [29,30]. In the remaining 10–15% of cancers, prevention
of telomere loss is achieved in the absence of telomerase activity,
through a recombination-mediated template switching mechanism
known as alternative lengthening of telomeres (ALT) [31].
Consequently, tumour cells are able to escape apoptosis and
hence maintain infinite replication capacity.
The DFTD cell line has been continuously dividing and
adapting to the microenvironment of each different host for over
15 years. Therefore this clonally transmitted disease provides an
unprecedented opportunity to study cancer cell evolution and
progression in vivo. Increased knowledge of telomere homeostasis
in this transmissible cancer may provide novel insights into how
DFT cells achieve and maintain their hyperproliferative potential
and may help us to understand the origins, somatic evolution and
extraordinary success of this parasitic clonal lineage. Furthermore,
both TERT and TINF2 have been suggested as potential
therapeutic targets in human cancer [32,33] and increasing our
understanding of the role of these genes in Devil Facial Tumour
Disease may open novel avenues for disease treatment.
In the present study we focused on the role of telomere length,
quantified as Telomere Copy Numbers (henceforth TCN) in
hyperproliferation of DFT samples. As proxies for telomerase
activity in tumour tissue samples we investigated the expression of
the catalytic subunit of telomerase (TERT) and one of the main
components of shelterin, the TRF1-intercating nuclear factor 2
(TINF2). Additionally, temporal changes in telomerase activity
were quantified in five DFT cell lines.
Results
(a) Telomere Restriction Fragment length analyses
Telomere restriction fragment (TRF) length was analysed in
both primary and metastastatic tumours, as well as spleen samples
from four Tasmanian devils (a total of 12 samples). We were
unable to assign telomere length in all of the 12 samples as the
restriction digest produced several repeated TRF-smears at
various lengths (ranging from ,2 kpbs up to ,18 kpbs) (Figure 1).
(b) Relative telomere repeat copy number
Altogether 65 tissue samples, collected from 17 locations across
Tasmania (Bothwell, Bronte Park, Buckland, Fentonbury, Forest-
ier, Freycinet, Hamilton, Mt William, Narawntapu, Railton,
Ravenswood, Reedy Marsh, Sorell, St. Marys, Weegena, Wisedale
and West Pencil Pine, Figure 2), were included in the relative
telomere repeat copy number analysis. Spleen, lung and tumour
samples exhibited a significant TCN variation (Kruskal Wallis test:
T= 17.1, P= 0.0007, DF= 3); with tumours (both primary and
metastatic) showing the lowest (mean= 3.2163.28) and spleen the
highest (mean= 12.5264.62), whereas lung samples showed
intermediate TCN (mean= 8.0362.04, Figure 3). A posthoc
Conover-Inman test (available in StatsDirect) revealed no signif-
icant difference in TCN between lung and spleen (P= 0.52),
between lung and metastasis (P = 0.08), between primary tumours
and metastasis (P = 0.52). The same test did, however, reveal a
significant difference in TCN between lung and primary tumours
(P = 0.006), between spleen and tumour (P= 0.0001), and between
spleen and metastasis (P = 0.01).
(c) Temporal (longitudinal) geographical and strain
variation in TCN
A Kruskal-Wallis test revealed a significant temporal variation
in TCN of samples collected in 2006, 2007 and 2010 (T=7.66,
P= 0.02, DF= 2) and a posthoc and a Conover-Inman test
revealed significant differences in TCN between years 2006 and
2007 (P = 0.03) and 2006 and 2010 (P= 0.01), but no significant
difference in TCN was observed between years 2007 and 2010
(P= 0.6). The post hoc test thus suggests a temporal increase in
TCN (Figure 4).
We did not however, observe any significant difference in TCN
among the three geographic regions (East, Central, North-West)
(Kruskal Wallis test: T= 1.75, P= 0.42, DF= 2), nor among the
four different strains (Kruskal Wallis test: T= 2.1, P = 0.56,
DF= 3).
(d) TERT and TINF2 expression
Devil TERT and TINF2 expression was significantly up-
regulated in primary tumours compared to spleen by a mean
factor of 14.63 P,0.0001 (Std. Error (SE) ranging between 4.5
and 37.8), and 37.86 P,0.0001 (SE ranging between 4.6–272.9),
respectively (Figure 5). TERT and TINF2 expression showed
Telomeres in DFTD
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substantial variation across tumour samples. We did not, however,
observe any significant association between TCN and TERT or
TINF2 expression in the tumour samples (Spearman rank
correlation, R=20.31, P= 0.36, N= 11; R=20.05, P= 0.88,
N= 11, respectively).
In the tumours, the expression level of TINF2 was significantly
lower than that of TERT (Two-sided Mann-Whitney U-test;
U=27, P= 0.03, median TINF2=0.51, median TERT=3.58).
Despite the difference in expression level we observed a significant
association between TERT and TINF2 (Spearman rank correlation
R=0.83, P = 0.0017, N= 11). We also detected a significant
temporal variation in TERT and TINF2 expression levels as both
TERT and TINF2 showed significantly increased expression levels
in 2010 compared to 2007 (Two sided Mann-Whitney U-test,
U= 28, P = 0.0173 and U=28.5, P= 0.013, respectively; TERT
median 4.77 and 2.44, respectively; TINF2 median 2.84 and 0.47,
respectively, Figure 6).
(e) Telomerase activity assay
Telomerase activity was detected in five of the DFT cell line
samples. Moreover, a positive temporal shift was observed in
telomerase activity (total product generated) from 2003 to 2011
(Spearman rank correlation, R=20.9, P= 0.037, N=5, Figure 7).
Discussion
Like many human cancers [34,35], Devil Facial Tumours have
short telomeres. TERT gene expression is up-regulated 15-fold in
DFT cells compared to spleen cells, and telomerase activity is
present in DFT cell lines. This telomerase activity prevents DFT
cells from entering replicative senescence, and taken together with
the lack of extrachromosomal telomeric DNA (Pearse pers. com)
in DFT karyotypes, points towards telomerase up-regulation, not
alternative lengthening of telomeres (ALT), as the primary
mechanism for DFT immortality [31].
High expression of TINF2, a negative regulator of telomerase
activity [23], in DFT cells suggests that telomere elongation is
highly regulated in this cancer. DFT cells appear to monitor and
regulate the length of individual telomeres i.e. shorter telomeres
are elongated by telomerase activity; longer telomeres are
protected from further elongation by the shelterin complex [27].
Increased TERT and TINF2 expression most likely explain the
lack of spatial variation in DFT TCN. Also, TCN does not differ
between DFTD strains. However, the temporal increase in TERT
and TINF2 gene expression and enzyme activity may be linked
Figure 1. The Telomere Restriction Fragment Length analysis
of devil samples revealed the presence of restriction enzyme
recognition sites intercalated between the telomeric
(TTAGGG)n sequences, preventing an accurate estimate of
TRF lengths. Sample names depict the time of collection (10= 2010).
Identical numbers represent different tissue samples collected from the
same animal, S depicts spleen and T depicts DFT samples. MWM stands
for molecular weight markers. CTRL 1 indicates low molecular weight
control DNA (length: 3.2 kbp), CTRL 2 indicates high molecular weight
control DNA (length: 10.2 kbp). Control samples were supplied in the
Telo TAGGG TL Assay Kit and originated from immortal cell lines.
doi:10.1371/journal.pone.0044085.g001
Figure 2. Tasmanian devil samples were collected from 17
locations across Tasmania. Tumour progression by 2003 depicted
with dashed, by 2005 with dashed-dotted and by 2007 with dotted
lines. Dates indicate the progression dates of DFTD. Location
abbreviations: Bo= Bothwell, Br = Bronte Park, Bu =Buckland, Fen = -
Fentonbury, For = Forestier, Fre = Freycinet, Ham=Hamilton, MtW=Mt
William, Na=Narawntapu, Ra = Railton, Rav = Ravenswood, Re= Reedy
Marsh, S = Sorell, StM = St. Marys, We =Weegena, Wi =Wisedale,
WPP=West Pencil Pine.
doi:10.1371/journal.pone.0044085.g002
Telomeres in DFTD
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e44085
with growth advantage and increased tumour progression in DFT,
as it is in human cancers [34,36,37].
The short telomeres and up-regulation of telomerase likely
counteract each other. The short telomeres lead to increased
genetic instability but the telomerase activation facilitates tumour
growth by either inhibiting further chromosomal instabilities or by
Figure 3. Relative telomere copy number is lower in DFT samples than in other devil tissues. Error bars depict standard deviations.
Sample names indicate the time of collection (06 = 2006, 07 = 2007, 10 = 2010). Identical numbers represent different tissue samples collected from
the same animal. Number of samples used in the analysis: primary tumours collected in 2006: N= 30, 2007: N= 13 and 2010: N = 8; metastasis: N = 4,
spleen: N= 5, lung: N = 5.
doi:10.1371/journal.pone.0044085.g003
Figure 4. Relative mean DFT telomere copy number increases
with time (2006: N=30, 2007: N=13 and 2010: N=8). Error bars
depict standard deviations. Significant differences in telomere copy
numbers (TCN) were observed between years 2006 and 2007 (P = 0.03)
and 2006 and 2010 (P = 0.01), but no significant difference in TCN was
observed between years 2007 and 2010 (P = 0.6). * indicates significant
differences.
doi:10.1371/journal.pone.0044085.g004
Figure 5. TERT and TINF2 genes are up-regulated in DFT
samples compared to spleen (P,0.0001). Number of samples
used in the analysis: tumours N= 11 and spleen N= 5. Stippled
horizontal lines depict mean relative gene expression, boxplots indicate
the range of standard error and bars depict 95% confidence intervals.
doi:10.1371/journal.pone.0044085.g005
Telomeres in DFTD
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circumventing checkpoints that recognise dysfunctional telomeres
[37]. Longer telomere lengths may ensure the success and survival
of DFT cells by stabilising chromosomal rearrangements and
preventing further genomic instabilities.
DFT samples exhibited consistently lower TCN compared to
other tissues, but a considerable (16-fold) among-sample variation
of TCN was observed. Methodological challenges, most likely
caused by interruption of telomeric repeats with restriction sites (a
common feature of marsupial chromosomes) [38], prevented us
from correlating variation in copy number to variation in
telomere length. TERT and TINF2 RNA levels did not associate
with TCN, a finding also observed in other human cancer cell
lines [39].
Future research should investigate the impact of telomere
length variation on tumour fitness. Is there an evolutionary
optimum around telomere length? Do selective forces maintain
telomere length equilibrium or select for tumour cells with longer
telomeres? Will increased TERT, TINF2 gene expression,
telomerase activity and longer telomeres lead to the development
of a more stable DFT form with higher growth and proliferative
potential?
Since its first appearance 15 years ago, DFTD has been passed
through thousands of devils, killing close to 80% of the animals,
without undergoing replicative senescence. DFTD thus represents
one of the oldest naturally living, and continuously passaged cell
lines in nature. We have shown that the dynamic interaction
between the telomerase and shelterin complex is essential to the
success of this parasitic, transmissible cancer. Selection has
promoted the progression of DFT cells with increased telomere
copy numbers as well as increased gene expression and telomerase
activity, both of which may ultimately lead to a faster growing
tumour. DFTD provides a powerful model system to understand
tumourigenesis not only in wildlife but also in human cancers.
Further studies focusing on understanding the exact mechanism of
telomere maintenance and regulation in DFT cells will lead to
better understanding of the evolutionary strategies and mecha-
nisms underlying and maintaining the unlimited proliferative
potential of cancer cells.
Materials and Methods
(a) Samples
Tissue samples were collected from 17 locations across
Tasmania (Bothwell, Bronte Park, Buckland, Fentonbury, Forest-
ier, Freycinet, Hamilton, Mt William, Narawntapu, Railton,
Ravenswood, Reedy Marsh, Sorell, St. Marys, Weegena, Wisedale
and West Pencil Pine, Figure 1) by the members of the
Department of Primary Industries, Parks, Water and Environment
(DPIPWE) from euthanised DFTD affected devils and stored at
the Animal Health Laboratories (DPIPWE). The research was
carried out with approval from the DPIPWE (Department of
Primary Industries, Parks, Water and Environment, Tasmania)
animal ethics comitte, Animal Ethics No: 101 2010/11. We
obtained tissue samples from 48 devils. We had access to spleen
and primary tumour, as well as metastasis samples from four
devils. 51 primary tumours, five metastases, four lung and five
spleen DNA samples were used in the analyses (Figure 2).
In order to investigate geographical/spatial variation in
telomere copy number, the samples were divided into three
geographical regions (East = distribution prior to 2003, Central = -
distribution between 2003–2005 and North-West = distribution
between 2005–2007) based on the temporal/spatial progression of
DFTD across Tasmania [40]. We had information about the
specific strains of 45 tumour samples and used these samples to
investigate telomere copy number variation between DFT strains.
Temporal variation in telomere attrition rates was based on
copy numbers observed in samples collected in 2006, 2007, and
2010 (N= 51). Due to sample collection procedures we were only
able to extract RNA from five spleen and 11 (5 from 2007 and 6
from 2010) primary tumour samples which were subsequently
analysed with the Quantitative Real-Time PCR.
The telomerase activity assays were performed on five lysed
DFT cell line samples obtained from DPIPWE. Tumour cell lines
were generated and maintained at DPIPWE according to the
descriptions of Pearse et al 2012 [11]. The five cell lines originated
from tumour samples collected in 2003, 2006, 2007, 2010 and
2011.
(b) DNA extraction, telomere fragment length
measurements and telomere copy number quantitation
Genomic DNA was isolated from tissue samples by phenol-
chloroform extraction. Sample DNA quantity and quality was
Figure 6. TERT and TINF2 gene expression increases with time
in DFT samples. Open bars depict TERT expression, black bars depict
TINF2 expression. Number of samples used in the analysis: tumours
collected in 2007: N= 5 and 2010: N = 6. * depicts significant differences
(P = 0.0173 and P= 0.013, respectively).
doi:10.1371/journal.pone.0044085.g006
Figure 7. Telomerase activity increases over time in DFT cell
lines (P=0.037). The five cell lines originated from tumour samples
collected in 2003, 2006, 2007, 2010 and 2011. Bars represent standard
errors between technical repeats (N = 3).
doi:10.1371/journal.pone.0044085.g007
Telomeres in DFTD
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measured using a NanoDrop Spectrophotometer (NanoDrop
Technologies, Wilmington, DE).
(c) Telomere Restriction Fragment Length analyses (TRFL)
Telomere restriction fragment (TRF) length was quantified by
Southern blot hybridisation following the protocol outlined in the
Telo TAGGG TL Assay Kit (Roche, Indianapolis, IN), using
constant field electrophoresis. After digesting genomic DNA with a
mixture of HinfI and RsaI restriction enzymes to remove sequence-
diverse DNA from the centromeric side of the telomeres, telomere
length was analysed on agarose gels, which were run for 4 hours at
5 V/cm. The TRF fragments were labeled with a digoxigen
labeled probe, and the TRF images were subsequently developed
on high performance chemiluminescence film (Amersham Biosci-
ence, Waukesha, WI).
(d) Quantitative PCR of relative telomere copy number
Relative telomere repeat copy number was analysed by
quantitative PCR (Q-PCR) as described by Cawthon [41].
Telomere specific primers were adopted from Cawthon [41],
Tel1: 59- GGTTTTTGAGGGTGAGGGTGAGGGTGAGGG-
TGAGGGT -39; Tel2, 59-TCCCGACTATCCCTATCCC-
TATCCCTATCCCTATCCCTA -39. RPLP0 (also called 36B4)
gene was chosen as single copy gene following the methodology of
Cawthon [41], and the single copy presence of this gene in the
Tasmanian Devil genome [42] was confirmed by searching the
genome for alternative copies of the gene. No alternative RPLP0
copies or pseudogenes were found. RPLP0 gene specific primers
were designed based on the Tasmanian Devil genome sequence
[42], using the Primer3Plus website (http://www.bioinformatics.
nl/cgi-bin/primer3plus/primer3plus.cgi), RPLP0_F: 59- CTTCC-
CGTTCACCAAAGAAG -39 and RPLP0_R: 59- TGTTCTG-
GACTGGCAAAGTG -39. The Q-PCR reactions were per-
formed on the RotorGene6000 (Qiagen, Germantown, MD) in
15 ml total volume, containing 7.5 ml of Qiagen 2xQuantifast Sybr
Green PCR master mix (Qiagen, Germantown, MD), 0.5 mM
forward and reverse primers (the optimal primer concentrations)
and 1 ml of gDNA (1 ng/ml concentration). Q-PCR conditions
were established according to the manufacturer protocol: 95uC for
5 min denaturation followed by 40 cycles of 95uC for 15 s and
60uC for 30 s (annealing temperature). Fluorescence signal was
acquired at the annealing temperature. Standard curves were
generated using serial 1:5 (RPLP0) and 1:10 (Telomere) dilutions of
a composite sample containing equal parts of DNA from spleen
and tumour tissue extracts. All dilutions were run in triplicate.
Standard curves had an R2.0.985 (RPLP0 reaction: R2= 0.985
and Telomere reaction R2= 0.997) and contained at least four
(Telomere reaction) or five (RPLP0 reaction) dilutions from the
dilution series with a linear dynamic range of at least 3 orders of
magnitude and had PCR efficiencies between 1.3 and 1.1
(respectively). All samples were run in quadruplicate, and all Cq
values for unknowns fell within the linear quantifiable range of the
appropriate standard curves. The program Rest [43] was used to
calculate the normalised fold change of the target gene compared
to the reference gene. This program package also corrects for
different reaction efficiencies. Statistical significance (P,0.05) was
determined by a Pair Wise Fixed Reallocation Randomisation
Test as described by Pfaffl et al .[43].
(e) RNA extraction and quantifying telomerase
expression by quantitative RT-PCR
RNA was extracted from tissue samples using a combination of
Trizol (Sigma, St. Louis, MO) and Qiagen RNeasy mini kit
(Qiagen, Germantown, MD). RNA quality and quantity were
quantified on an Agilent 2100 BioAnalyzer (Agilent, Santa Clara,
CA). Genomic DNA was removed from the RNA samples by the
DNAse I AMPD1 kit (Sigma, St. Louis, MO) and cDNA was
synthesized with the QuantiTect Reverse Transcription Kit
(Qiagen, Germantown, MD). Telomerase gene specific primers
spanning exon boundaries were designed in the catalytic protein
subunit of devil TERT gene, using the Primer3Plus website
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.
cgi) TERT-F: 59- TGCTGTAGTCCAGAAGAATGC -39, and
TERT-R: 59- TGCAGGGAAGAGGTTTCTTG -39. TRF1-
interacting nuclear factor 2 (TINF2) primers were designed across
exons 6 and 7 TINF2-F: 59- TTGCCCTGACTCAGTATTGC -
39, and TINF2-R: 59- GGATCCTGGAAAACTTGCTC -39.
Two genes, GAPDH (qGAPDH) and GUSB (qGUSB) were used as
normaliser genes following the description of Murchison et
al.[10,14]: qGAPDHf: 59- GACTCAACCACGTATTCGGCTC
-39and qGAPDHr: 59- ATATGATTCCACCCATGGCAAGTT-
CAA -39; qGUSBf: 59- CTGCTGCCTATTATTTCAAGAC -
39and qGUSBr: 59-CAAGATCCAATTCAGGCTTAG -39. The
Q-PCR reactions were performed on the RotorGene6000
(Qiagen, Germantown, MD) in 15 ml total volume, containing
7.5 ml of Qiagen 2xQuantifast Sybr Green PCR master mix
(Qiagen, Germantown, MD), 0.5 mM forward and reverse primers
(the optimal primer concentrations) and 1 ml of cDNA (5 ng/ml
concentration). Reverse transcriptase negative and cDNA negative
samples were run alongside the cDNA samples as controls to
detect genomic DNA contamination and primer-dimer forma-
tions. Q-PCR conditions were established according to the
manufacturer protocol: 95uC for 5 min denaturation followed by
40 cycles of 95uC for 15 s and 60uC for 30 s (annealing
temperature, AT). Fluorescence signal was acquired at the AT.
To evaluate the specific amplification a final melting curve analysis
(from AT up to 99uC) was added under continuous fluorescence
measurements. Standard curves were generated using serial 1:5
dilutions of a composite sample containing equal parts of cDNA
samples generated from spleen and tumour tissue RNA extracts.
All dilutions were run in triplicate. Standard curves had an
R2.0.99 (GUSB reaction: R2= 0.998, TERT reaction: R2= 0.990
and TINF2 reaction: R2= 0.993) and contained at least four
(TERT reaction) or five (GUSB and TINF2 reactions) dilutions
from the dilution series with a linear dynamic range of at least 3
orders of magnitude and had PCR efficiencies between 0.98 and
1.4 (GUSB: 1.1, TERT: 1.4 and TINF2: 0.98). All samples were run
in quadruplicate, and all Cq values for unknowns fell within the
linear quantifiable range of the appropriate standard curves. The
program Rest [43] was used to calculate the normalized fold
change of the target gene compared to the reference gene. This
program package also corrects for the different reaction efficien-
cies. Statistical significance (P,0.05) was determined by a Pair
Wise Fixed Reallocation Randomisation Test as described by
Pfaffl et al. [43].
(f) Telomerase assay
Telomerase activity was measured using the TRAPEZE-RT
telomerase detection kit (Millipore, Bedford, MA). Cells were lysed
in 200 ml of CHAPS buffer, and protein content was quantified by
using the Pierce BCA Protein Assay Kit (Thermo Scientific,
Rockford, IL). Aliquots of cell lysate (250 ng of protein/well) were
assayed in triplicate. Standards, inactivated samples, and non-
template reactions were also included in the assay as quality
controls. Real-time amplifications were performed with a
RotorGene6000 multicolor real-time PCR detection system
(Qiagen, Germantown, MD). Standard curve was generated from
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TSR8 control template following the manufacturer’s instructions.
Telomerase activity (total product generated) was calculated by
extrapolating the average Ct values from the sample wells to the
standard curve.
(g) Statistical analyses
Relative quantifications of telomere copy numbers and gene
expression were performed using sample crossing points, and data
was analysed with the RotorGene6000 software 1.7. (Qiagen,
Germantown, MD), applying the ‘‘second derivative maximum’’
method [44]. The Excel application Best-Keeper [43] was used to
check the data for statistical significance, normality and reliability,
and the normaliser gene GUSB was chosen as reference based on
BestKeeper calculations [45]. The program Rest [43] was used to
calculate the normalised fold change of the target gene compared
to the reference gene. Statistical significance (P,0.05) was
determined by a Pair Wise Fixed Reallocation Randomisation
Test as described by Pfaffl et al. [43]. When data could not be
transformed to achieve normality non-parametric statistics were
applied using the software packages StatsDirect and JMPv5
[46,47].
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